Cardurion Pharmaceuticals, a biotechnology company in the clinical stage, has announced a successful Series B financing round raising $260 million. Leading the round was Ascenta Capital, joined by new investors NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, and Digitalis Ventures, along with existing investors Bain Capital Life Sciences and Bain Capital Private Equity.

This funding will primarily support advanced clinical trials for Cardurion's two main drug candidates: a first-of-its-kind phosphodiesterase-9 (PDE9) inhibitor for heart failure and a Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor with broad therapeutic potential. It will also enable Cardurion to expand into new cardiovascular indications, progress internal discovery programs, and acquire strategic assets addressing unmet needs in cardiovascular disease.

Cardurion, highlighted their commitment to developing innovative cardiovascular therapies, given that cardiovascular diseases remain a leading global cause of death. He emphasized the successful translation of scientific insights into clinical advancements with their PDE9 and CaMKII inhibitor programs, now progressing to later-stage clinical trials to assess efficacy in patients.

Following promising clinical validation of their PDE9 inhibitor, CRD‑750, Cardurion has initiated Phase 2 trials involving 640 patients with heart failure types HFrEF and HFpEF. Simultaneously, their Phase 2 trial for the CaMKII inhibitor, CRD-4730, targets catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmic disorder. Future plans include exploring CaMKII inhibitors across additional significant cardiovascular indications.

The funding influx will facilitate team expansion and bolster capabilities in cardiovascular drug innovation. As part of the financing, Ascenta Capital’s Evan Rachlin, GV’s Dan Lynch, and NEA’s Ed Mathers will join Cardurion’s Board of Directors, providing strategic guidance and support for the company’s mission to advance transformative therapies for cardiovascular patients.

 

Source: businesswire.com

Report Abuse